

Draft - February 9, 2021

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

February 24-25, 2021

<u>AGENDA ITEM</u>		<u>PRESIDER/PRESENTER(s)</u>
<u>Wednesday, February 24, 2021</u>		
9:30	Welcome & Introductions	Dr. José Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
10:00	Rabies Vaccines Introduction Summary of Pre-exposure prophylaxis (PrEP) considerations including cost of PrEP, GRADE, and EtR Background about rabies post-exposure prophylaxis Workgroup interpretations about rabies immune globulin Summary and next steps	Dr. Sharon Frey (ACIP, WG Chair) Dr. Agam Rao (CDC/NCEZID) Dr. Agam Rao (CDC/NCEZID) Dr. Agam Rao (CDC/NCEZID) Dr. Agam Rao (CDC/NCEZID)
12:00	Break	
12:30	Public Comment	
1:00	Votes Rabies Vaccines	Dr. Agam Rao (CDC/NCEZID)
1:20	Dengue Vaccine Introduction Results of dengue test independent evaluation Draft recommendations using the Evidence to Recommendations Framework	Dr. Kathy Poehling (ACIP, WG Chair) Dr. Freddy Medina (CDC/NCEZID) Dr. Gabriela Paz-Bailey (CDC/NCEZID)
2:20	Tick-borne Encephalitis (TBE) Vaccine Introduction TBE epidemiology in TBE endemic areas TBE among US civilian travelers and laboratory workers TBE among military personnel and dependents Summary of risks of TBE for U.S. travelers and laboratory workers and next steps	Dr. Kathy Poehling (ACIP, WG Chair) Dr. Susan Hills (CDC/NCEZID) Dr. Erin Staples (CDC/NCEZID) Dr. Bruce McClenathan (DOD) Dr. Susan Hills (CDC/NCEZID)
3:30	Break	
3:40	Ebola Vaccine Introduction Background on state designated Ebola Treatment Centers (ETC) and Laboratory Response Network (LRN) facilities and survey results Review of preliminary workgroup discussions	Dr. Sharon Frey (ACIP, WG Chair) Ms. Allison Joyce (CDC/NCEZID) Dr. Caitlin Cossaboom (CDC/NCEZID)
4:45	Hepatitis Vaccine Introduction Background Economic analysis	Dr. Sharon Frey (ACIP, WG Chair) Dr. Mark Weng (CDC/NCHHSTP) Dr. Eric Hall (Emory University)
5:30	Adjourn	
<u>Thursday, February 25, 2021</u>		
9:30	Welcome & Introductions	Dr. José Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC)
9:40	Agency Updates	
10:00	Pneumococcal Vaccines Introduction Current epidemiology of pneumococcal disease and pneumococcal vaccine coverage in US adults PCV20 Phase 2/3 study results in adults PCV15 Phase 2/3 study results in adults, including adults with underlying conditions Considerations for PCV15 and PCV 20 use in adults	Dr. Kathy Poehling (ACIP, WG Chair) Mr. Ryan Gierke (CDC/NCIRD) Dr. Wendy Watson (Pfizer) Dr. Ulrike Buchwald (Merck) Dr. Miwako Kobayashi (CDC/NCIRD)
12:00	Break	
12:20	Zoster Vaccines Introduction Risk of Guillain-Barré syndrome (GBS) following recombinant zoster vaccine (RZV) RZV risk-benefit analysis Work group interpretation	Dr. Grace Lee (ACIP, WG Chair) Dr. Richard Forshee (FDA/CBER) Dr. Lisa Prosser (University of Michigan) Dr. Tara Anderson (CDC/NCIRD)

Draft - February 9, 2021

Introduction of the Evidence to Recommendations Framework for use of RZV in immunocompromised adults

Dr. Tara Anderson (CDC/NCIRD)

1:30	Influenza Vaccines	
	Introduction	Dr. Keipp Talbot (ACIP, WG Chair)
	Influenza surveillance update	Dr. Lisa Grohskopf (CDC/NCIRD)
	Work group considerations	Dr. Lisa Grohskopf (CDC/NCIRD)
2:15		
2:25	Cholera Vaccine	
	Introduction	Dr. Pablo Sanchez (ACIP, WG Chair)
	Introduction to cholera and cholera vaccines	Dr. Jennifer Collins (CDC/NCEZID)
	Vaxchora safety and immunogenicity data	Dr. James McCarty (Emergent BioSolutions)
	Work group plans	Dr. Jennifer Collins (CDC/NCEZID)
3:25	Orthopoxviruses Vaccines	
	Introduction	Dr. Beth Bell (ACIP, WG Chair)
	Workgroup considerations	Dr. Brett Petersen (CDC/NCEZID)
	Updated policy questions and progress on systematic review	Dr. Agam Rao (CDC/NCEZID)
	Summary and next steps	Dr. Brett Petersen (CDC/NCEZID)
5:35	Adjourn	

Acronyms

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
PCV15	15-valent pneumococcal conjugate vaccine
PCV20	20-valent pneumococcal conjugate vaccine
PEP	Post-exposure prophylaxis
PrEP	Pre-exposure prophylaxis
RZV	Recombinant zoster vaccine
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness